Chronic Myelomonocytic Leukemia

Research output: Chapter in Book/Report/Conference proceedingChapter


This chapter discusses chronic myelomonocytic leukemia (CMML), a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms. The incidence of CMML has been approximated at 12.8 cases per 100,000 people per year, with the median age of presentation being 65-75 years. Cytogenetic abnormalities in CMML can be detected by conventional karyotyping or fluorescent in situ hybridization (FISH) studies. The treatment for CMML can be broadly divided into two categories: supportive care and directed or targeted therapy. Supportive care focuses on symptom management and palliation, and it comes into play when patients are ineligible for, or have failed, directed therapy. For directed or targeted therapy, the hypomethylating agents 5-azacitidine and decitabine have been approved by the US Food and Drug Administration for MDS. These agents have been used in CMML with varying success, and allogeneic stem cell transplantation remains the only curative option for patients with CMML. This technique is, however, fraught with complications, such as graft rejection, nonrelapse mortality (NRM), acute and chronic graft-versus-host disease (GVHD), organ injury, and disease relapse in the posttransplant period.

Original languageEnglish (US)
Title of host publicationCancer Consult
Subtitle of host publicationExpertise for Clinical Practice
Number of pages4
ISBN (Electronic)9781118589199
ISBN (Print)9781118589212
StatePublished - Jun 20 2014


  • Chronic myelomonocytic leukemia (CMML)
  • Directed or targeted therapy
  • Fluorescent in situ hybridization (FISH)
  • Karyotyping
  • Supportive care

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Chronic Myelomonocytic Leukemia'. Together they form a unique fingerprint.

Cite this